Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

Inclusion Criteria:

* Histologically confirmed CD30+ classical Hodgkin lymphoma
* Supradiaphragmatic Ann Arbor clinical stage I or II
* Previously untreated
* PET scan without IV contrast at diagnosis available for central review with at least one hypermetabolic lesion
* Unfavourable (U) characteristics according to the classic EORTC/LYSA clinical prognostic factors, including patients with at least one of the following factors:

  * CSII ≥ 4 nodal areas
  * age ≥ 50 yrs
  * M/T ratio ≥ 0.35
  * ESR ≥ 50 (without B-symptoms) or ESR ≥ 30 with B-symptoms
* ECOG performance status 0-2
* Life expectancy \> 6 months
* Age 18 to 60 years
* Availability for periodic blood sampling, study-related assessments, and management of toxicity at the treating institution.
* Female patients who:

  * Are postmenopausal for at least 1 year before the screening visit, OR are surgically sterile, OR
  * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, through 6 months after the last dose of study drug, OR agree to completely abstain from heterosexual intercourse
* Male patients, even if surgically sterilized (ie, status postvasectomy), who:

  o Agree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.
* Written informed consent.
* Required baseline laboratory data:

  * Absolute neutrophil count ≥ 1,500/µL
  * Platelet count ≥ 75,000/ µL
  * Hemoglobin ≥ 8g/dL
  * Serum total bilirubin ≤ 1.5 X ULN unless the elevation is known to be due to Gilbert syndrome.
  * Serum creatinine ≤ 2.0 mg/dL and/or calculated creatinine clearance \> 40 mL/minute (Cockcroft-Gault formula or MDRD)
  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 X ULN

Exclusion Criteria:

* Histological diagnosis different from classical Hodgkin Lymphoma. Nodular lymphocyte predominant subtypes (nodular paragranuloma or Poppema paragranuloma) are excluded.
* Known cerebral or meningeal disease of any etiology, including signs or symptoms of PML
* Any sensory or motor peripheral neuropathy ≥ Grade 2
* Known history of any of the following cardiovascular conditions

  * Myocardial infarction within 2 years of randomization
  * New York Heart Association (NYHA) Class III or IV heart failure (see Appendix 14)
  * Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
  * Recent evidence (within 30 days before first dose of study drug) of a left-ventricular ejection fraction \<50%
* Unstable diabetes mellitus (to avoid uninterpretable FDG-PET scan).
* Known HIV positive
* HCV positive
* HBV positive. This means:

  * HBsAg positive
  * HBsAg negative, anti-HBs positive and/or anti-HBc positive and detectable viral DNA (HBsAg negative patients and viral DNA negative and patients seropositive due to a history of hepatitis B vaccine are eligible).
* Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors. Carcinoma in situ of any type not excluded if complete resection.
* Dementia or altered mental status
* Pregnancy or breastfeeding.
* Previous treatment with any anti-CD30 antibody.
* Known hypersensitivity to any excipients contained in the BV formulation or known contra-indication to any drug contained in the chemotherapy regimens
* Treatment with corticosteroids before baseline PET scan
* Known active viral, bacterial, or fungal infection requiring treatment with antimicrobial therapy or with untreated known active Grade 3 viral, bacterial, or fungal infection, within 2 weeks prior to the first dose of BV
* Treatment with any investigational drug within 30 days before first cycle of treatment